Market Overview

UPDATE: Wedbush Raises PT to $13 on Sangamo BioSciences on HIV Progress, Time Value

Related SGMO
Is Sangamo The Next Biotech Stock To Break Out?
Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms

Wedbush maintained Sangamo BioSciences (NASDAQ: SGMO) with an Outperform rating and raised the price target from $10.00 to $13.00.

Wedbush said, "Sangamo presented immunologic results supporting previous observations about the functionality and durability of SB-728-T modified T-cells at the 20th Conference on Retroviruses and Opportunistic Infections (CROI). … We are reiterating our OUTPERFORM rating and increasing our fair value to $13 from $10 due to HIV progress, error correction, and time value. By focusing on CCR5 heterozygotes, we increased our peak penetration and net peak annual worldwide revenues to Sangamo to about $656 million from about $500 million."

Sangamo BioSciences closed at $10.26 on Wednesday.

Latest Ratings for SGMO

DateFirmActionFromTo
Sep 2014JefferiesInitiates Coverage onBuy
Aug 2014JP MorganInitiates Coverage onOverweight
Jun 2013Cowen & CompanyInitiates Coverage onOutperform

View More Analyst Ratings for SGMO
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Analyst Ratings

 

Related Articles (SGMO)

Around the Web, We're Loving...

Get Benzinga's Newsletters